This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RXi Pharmaceuticals Awarded $580,000 In NIH Grants To Advance RNAi Therapeutics

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH).

ALS Research Support. The National Institute of Neurological Disorders and Stroke (NINDS/NIH) will provide funding for an ongoing collaboration between RXi Pharmaceuticals and Robert Brown, MD, DPhil, Chair of the Department of Neurology at the University of Massachusetts Medical School in Worcester that is focused on the preclinical development of novel RNAi therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. The project aims to generate an optimized self-delivering RNAi compound (sd-rxRNA™) for ALS that can be moved into clinical development as well as establish an optimized sd-rxRNA platform for spinal cord delivery. RXi was awarded $304,559 for Phase I of the project and may apply for additional Phase II funding to continue its research in this area.

RNAi Chemical Optimization Project. A grant from the National Institute of General Medical Sciences (NIGMS) will provide funding for a project seeking to improve the delivery of RNAi therapeutics through medicinal chemistry. More specifically, RXi will explore further chemical optimization of its sd-rxRNA compounds to improve in vivo potency and expand bio-distribution for clinical applications. RXi was awarded $273,824 for Phase I of the project and may apply for additional Phase II funding to continue its research in this area.

“We are pleased to have received support for our innovative research programs that could have a significant impact on our progress lead to powerful new approaches to therapy,” said Anastasia Khvorova, Ph.D. Chief Scientific Officer of RXi Pharmaceuticals. “The funding of these grants reflects the strength of our scientific team, demonstrated progress, and our determination to successfully meet the delivery challenge of RNAi therapeutics with our unique sd-rxRNA technology.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs